Meeting slides
Suggested Readings

Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.

Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.

Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]

Early remdesivir to prevent progression to severe Covid-19 in outpatients.

Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.

Neutralization escape by the SARS-CoV-2 Omicron variants BA.2.12.1 and BA.4/BA.5.

Hachmann NP, Miller J, Collier A-rY, et al. medRxiv. 2022. [Epub ahead of print]

Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.

Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.

At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.

Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.

Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.

Levin M, Ustianowski A, De Wit S, et al. N Engl J Med. 2022. [Epub ahead of print]

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.

Montgomery H, Hobbs FDR, Padilla F, et al. Lancet Respir Med. 2022;10(10):985-996.

Data and clinical considerations for additional doses in immunocompromised people.

Oliver S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; July 22, 2021.

A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model.

Razonable RR, Aloia NCE, Anderson RJ, et al. Mayo Clin Proc. 2021;96(5):1250-1261.

Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.

Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.

Related activities

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Faculty: Eric Daar, MD; Lucy Horton, MD; Raymund Razonable, MD; Lewis Teperman, MD; Phyllis Tien, MD; Charles Vega, MD
Release: 10/31/2022
Expiration: 10/31/2023